Chart Analysis
IMU Daily Timeframe Chart as of 22 May 2026
Imugene (ASX: IMU) Azer-cel Hits 81% Response Rate in CAR T-Naïve Blood Cancer Patients — ASCO 2026 Abstract Ahead of Chicago Oral Presentation
An 81% overall response rate across six blood cancer subtypes from an off-the-shelf CAR T therapy that no company has ever brought to regulatory approval globally. That is the headline from Imugene's ASCO 2026 abstract for azer-cel, published on 22 May 2026 ahead of an oral presentation scheduled for 29 May in Chicago. Among 16 evaluable CAR T-naïve patients, 13 responded — including 100% response rates in MZL (4 patients), CLL (3 patients), FL (1 patient), and WM (1 patient). The stock moved +35.4% to $0.130, closing on the session high. But the data comes with significant caveats: 16 patients, Day 28 assessment only, no durability data, and individual subtype results based on 1–5 patients each.
Response Data by Subtype — Small Numbers, Broad Activity
| Subtype | Evaluable | ORR | CR | PR |
|---|---|---|---|---|
| DLBCL | 5 | 60% | 1 | 2 |
| MZL | 4 | 100% | 3 | 1 |
| CLL | 3 | 100% | 0 | 3 |
| PCNSL | 2 | 50% | 0 | 1 |
| FL | 1 | 100% | 1 | 0 |
| WM | 1 | 100% | 0 | 1 |
| Total | 16 | 81% | 5 | 8 |
The data comes from Cohort 2 (CAR T-naïve) of an ongoing Phase 1b basket study. Patients had relapsed or refractory B-cell malignancies and had not previously received autologous CAR T therapy. Several had received multiple prior lines including bispecific antibodies and autologous stem cell transplant. Azer-cel was administered in combination with low-dose IL-2 to support CAR T-cell expansion and persistence.
The breadth of activity across six subtypes from a single off-the-shelf product is the most noteworthy aspect of the data. The depth of any individual subtype response cannot be assessed from 1–5 patients.
Why Allogeneic CAR T Matters — And Why It's Unproven
Azer-cel is an allogeneic (off-the-shelf) CD19-targeting CAR T therapy manufactured from donor cells in advance, unlike approved autologous products (Kymriah, Yescarta, Breyanzi, Tecartus) that require harvesting each patient's own T-cells and manufacturing a personalised product over several weeks. The potential advantages — faster access, lower per-patient manufacturing cost, broader scalability — are significant if the biological challenges can be overcome.
Those challenges are real. Host-versus-graft and graft-versus-host immune reactions can limit CAR T-cell persistence and efficacy. No allogeneic CAR T therapy has received regulatory approval anywhere in the world. Several competitors' allogeneic programs (including from CRISPR Therapeutics, Caribou Biosciences, and Precision BioSciences) have been discontinued or restructured due to insufficient efficacy or persistence. Azer-cel's combination with low-dose IL-2 is designed to address the persistence challenge, but whether this approach works durably in humans remains to be demonstrated.
The Upcoming ASCO Oral Presentation and New BTKi Cohort
An oral presentation with an updated dataset (ASCO Abstract #7012) is scheduled for 29 May 2026 at the ASCO Annual Meeting in Chicago (1:00 PM CDT). Oral presentation slots at ASCO are competitively allocated and are considered a favourable signal for data quality and relevance.
Imugene has also opened Cohort 3 evaluating azer-cel in combination with a BTK inhibitor for patients who previously failed BTKi therapy, with Mantle Cell Lymphoma (MCL) added as an indication. The global BTKi market reached approximately US$12.0 billion in 2025.
Risks & Considerations
Sixteen evaluable patients at Day 28 is an early dataset by any clinical standard. No duration of response, progression-free survival, or overall survival data has been disclosed — responses that don't last are of limited clinical value, and durability is the central question for allogeneic CAR T where persistence has historically been the failure mode. The pathway from Phase 1b to regulatory approval is typically multi-year and requires successful pivotal Phase 2 or Phase 3 trials, which have not commenced.
The 100% response rates in MZL, CLL, FL, and WM are from 1–4 patients each — sample sizes too small to draw statistically meaningful conclusions about efficacy in any specific indication. DLBCL, the largest subtype cohort at 5 patients, showed a 60% ORR — lower than the approved autologous CAR T products in this indication (typically 50–80% CR rates in pivotal trials, with durable responses).
Imugene is a clinical-stage company with FY2025 revenue of A$4.40 million, losses of approximately A$58.5 million (H1 FY2026), and a market capitalisation of approximately A$61–72 million. The company requires ongoing funding to support its multi-program clinical pipeline (azer-cel, CF33 Vaxinia oncolytic virus, onCARlytics, HER-Vaxx, PD1-Vaxx, NeoPOLEM).
Key Dates & Timeline
| Date | Event |
|---|---|
| 22 May 2026 | ASCO abstract #7012 published; share price moved +35.4% |
| 29 May 2026 | Oral presentation at ASCO Annual Meeting, Chicago (1:00 PM CDT) |
| Recently opened | Cohort 3 — azer-cel + BTKi (including MCL indication) |
| Ongoing | Phase 1b basket study enrolment |
| TBC | Clinical development strategy informed by ASCO data |
Price Data
- Previous Close: $0.096
- Close Price (22 May 2026): $0.130
- Change (22 May 2026): +35.4%
- 52-Week Range: $0.090 – $0.612
Notable Price Levels
-
$0.612 — 52-week high from H1 2025, set during a period of broader pipeline enthusiasm (Vaxinia/CF33 clinical data, initial azer-cel results). The stock subsequently declined approximately 85% to the $0.090 52-week low. At ~371% above the announcement-day close, this level illustrates the magnitude of the decline that preceded this data release — the ASCO abstract has recovered only a fraction of the peak-to-trough move.
-
$0.130 — announcement-day close on the session high. The zero close-to-high spread indicates sustained buying throughout the session. At this level, IMU's market capitalisation is approximately A$61–72 million — modest for a clinical-stage biotech with an 81% ORR dataset at ASCO, reflecting the market's awareness of the small patient numbers and early-stage nature of the data.
-
$0.096 — undisturbed close and the base from which the stock rallied. IMU had been consolidating around $0.090–$0.100 for several weeks near its 52-week low. A retracement here would fully unwind the ASCO abstract premium.
-
$0.090 — 52-week low and the structural floor of the stock's 12-month decline. At this level, the market had priced IMU at its most pessimistic valuation despite the multi-program pipeline — reflecting accumulated disappointment from the ~85% decline since the H1 2025 peak.
Summary
Imugene's allogeneic CAR T therapy azer-cel achieved an 81% overall response rate across 16 evaluable CAR T-naïve patients with relapsed or refractory blood cancers — with activity across six B-cell malignancy subtypes including 100% ORR in MZL, CLL, FL, and WM — as published in ASCO Abstract #7012 on 22 May 2026. The stock moved +35.4% to $0.130 on the session high. An oral presentation with updated data is scheduled for 29 May 2026 at the ASCO Annual Meeting in Chicago. No allogeneic CAR T therapy has received regulatory approval globally, and the data comes from a Phase 1b study with 16 evaluable patients at Day 28 assessment only — no durability, PFS, or OS data has been reported. Individual subtype results are based on 1–5 patients each. Imugene has opened a BTKi combination cohort (Cohort 3, including MCL) and requires ongoing funding for its multi-program clinical pipeline.
This article is for informational purposes only and does not constitute financial advice. Market Flow does not recommend buying or selling any securities. Past performance is not indicative of future results. Readers should conduct their own independent research and consult a licensed financial adviser before making any investment decisions. This content is published in accordance with ASX Market Rules and is not a financial product recommendation.
